InsidersTradesSigma
Apollomics Inc.: directors' dealings · United States · SEC (Form 4)
Explore the full insider trade history of Apollomics Inc., a listed equity based in United States. Shares are quoted on US US, under the oversight of SEC (Form 4). Market capitalisation: €46m. The latest transaction was reported on 17 June 2026 (Levée d'options). Among the most active insiders: LIN PETER KUAN-HOW. All data is accessible without an account.
8
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
·
0 ops.
Sell Volume
22Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 17 June 2026
Declarations8 total
10,000 sharesCLASS A ORDINARY SHARESSEC:0001193125-26-274552:0
3,588 sharesCLASS A ORDINARY SHARESSEC:0001193125-26-274552:1
500 sharesCLASS A ORDINARY SHARESSEC:0001193125-26-272821:0
5,000 sharesCLASS A ORDINARY SHARESSEC:0001193125-26-272823:0
500 sharesCLASS A ORDINARY SHARESSEC:0001193125-26-272835:0
500 sharesCLASS A ORDINARY SHARESSEC:0001193125-26-272849:0
5,000 sharesCLASS A ORDINARY SHARESSEC:0001193125-26-272860:0
8 of 8 declarations
About Apollomics Inc.
Apollomics Inc. is a biopharmaceutical company focused on developing innovative treatments for cancer. It is listed on the NASDAQ under the ticker APLM.